Literature DB >> 19915793

Relevance of allosteric conformations and homocarnosine concentration on carnosinase activity.

Verena Peters1, Moustafa Kebbewar, Erwin W Jansen, Cornelis Jakobs, Eva Riedl, Hannes Koeppel, Dirk Frey, Katja Adelmann, Kristina Klingbeil, Matthias Mack, Georg F Hoffmann, Bart Janssen, Johannes Zschocke, Benito A Yard.   

Abstract

Activity of carnosinase (CN1), the only dipeptidase with substrate specificity for carnosine or homocarnosine, varies greatly between individuals but increases clearly and significantly with age. Surprisingly, the lower CN1 activity in children is not reflected by differences in CN1 protein concentrations. CN1 is present in different allosteric conformations in children and adults since all sera obtained from children but not from adults were positive in ELISA and addition of DTT to the latter sera increased OD450 values. There was no quantitative difference in the amount of monomeric CN1 between children and adults. Further, CN1 activity was dose dependently inhibited by homocarnosine. Addition of 80 microM homocarnosine lowered V (max) for carnosine from 440 to 356 pmol/min/microg and increased K (m) from 175 to 210 microM. The estimated K (i) for homocarnosine was higher (240 microM). Homocarnosine inhibits carnosine degradation and high homocarnosine concentrations in cerebrospinal fluid (CSF) may explain the lower carnosine degradation in CSF compared to serum. Because CN1 is implicated in the susceptibility for diabetic nephropathy (DN), our findings may have clinical implications for the treatment of diabetic patients with a high risk to develop DN. Homocarnosine treatment can be expected to reduce CN1 activity toward carnosine, resulting in higher carnosine levels.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19915793     DOI: 10.1007/s00726-009-0367-z

Source DB:  PubMed          Journal:  Amino Acids        ISSN: 0939-4451            Impact factor:   3.520


  9 in total

1.  CNDP1 knockout in zebrafish alters the amino acid metabolism, restrains weight gain, but does not protect from diabetic complications.

Authors:  Felix Schmöhl; Verena Peters; Claus Peter Schmitt; Gernot Poschet; Michael Büttner; Xiaogang Li; Tim Weigand; Tanja Poth; Nadine Volk; Jakob Morgenstern; Thomas Fleming; Peter P Nawroth; Jens Kroll
Journal:  Cell Mol Life Sci       Date:  2019-05-09       Impact factor: 9.261

2.  N-glycosylation of carnosinase influences protein secretion and enzyme activity: implications for hyperglycemia.

Authors:  Eva Riedl; Hannes Koeppel; Frederick Pfister; Verena Peters; Sibylle Sauerhoefer; Paula Sternik; Paul Brinkkoetter; Hanswalter Zentgraf; Gerjan Navis; Robert H Henning; Jacob Van Den Born; Stephan J L Bakker; Bart Janssen; Fokko J van der Woude; Benito A Yard
Journal:  Diabetes       Date:  2010-05-11       Impact factor: 9.461

Review 3.  Carnosinase, diabetes mellitus and the potential relevance of carnosinase deficiency.

Authors:  Verena Peters; Johannes Zschocke; Claus P Schmitt
Journal:  J Inherit Metab Dis       Date:  2017-10-13       Impact factor: 4.982

4.  Intrinsic carnosine metabolism in the human kidney.

Authors:  Verena Peters; Celine Q F Klessens; Hans J Baelde; Benjamin Singler; Kimberley A M Veraar; Ana Zutinic; Jakub Drozak; Johannes Zschocke; Claus P Schmitt; Emile de Heer
Journal:  Amino Acids       Date:  2015-07-24       Impact factor: 3.520

5.  Muscle histidine-containing dipeptides are elevated by glucose intolerance in both rodents and men.

Authors:  Sanne Stegen; Inge Everaert; Louise Deldicque; Silvia Vallova; Barbora de Courten; Barbara Ukropcova; Jozef Ukropec; Wim Derave
Journal:  PLoS One       Date:  2015-03-24       Impact factor: 3.240

6.  Allosteric inhibition of carnosinase (CN1) by inducing a conformational shift.

Authors:  Verena Peters; Claus P Schmitt; Tim Weigand; Kristina Klingbeil; Christian Thiel; Antje van den Berg; Vittorio Calabrese; Peter Nawroth; Thomas Fleming; Elisabete Forsberg; Andreas H Wagner; Markus Hecker; Giulio Vistoli
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

7.  Correlation between serum carnosinase concentration and renal damage in diabetic nephropathy patients.

Authors:  Zhou Zhou; Xue-Qi Liu; Shi-Qi Zhang; Xiang-Ming Qi; Qiu Zhang; Benito Yard; Yong-Gui Wu
Journal:  Amino Acids       Date:  2021-04-03       Impact factor: 3.520

8.  Monoclonal Antibody RYSK173 Recognizes the Dinuclear Zn Center of Serum Carnosinase 1 (CN-1): Possible Consequences of Zn Binding for CN-1 Recognition by RYSK173.

Authors:  Shiqi Zhang; Holger A Lindner; Sarah Kabtni; Jaap van den Born; Stephan Bakker; Gerjan Navis; Bernard Krämer; Benito Yard; Sibylle Hauske
Journal:  PLoS One       Date:  2016-01-22       Impact factor: 3.240

9.  Serum Carnosinase-1 and Albuminuria Rather than the CNDP1 Genotype Correlate with Urinary Carnosinase-1 in Diabetic and Nondiabetic Patients with Chronic Kidney Disease.

Authors:  Angelica Rodriguez-Niño; Sibylle J Hauske; Anna Herold; Jiedong Qiu; Jacob van den Born; Stephan J L Bakker; Bernhard K Krämer; Benito A Yard
Journal:  J Diabetes Res       Date:  2019-12-24       Impact factor: 4.011

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.